Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from Philogen SpA ( (IT:PHIL) ) is now available.
Philogen S.p.A. has made available the minutes of its Shareholders’ Meeting held on April 29, 2025. This announcement underscores the company’s commitment to transparency and governance, potentially reinforcing stakeholder confidence and supporting its strategic objectives in the biotechnology sector.
The most recent analyst rating on (IT:PHIL) stock is a Buy with a EUR25.00 price target. To see the full list of analyst forecasts on Philogen SpA stock, see the IT:PHIL Stock Forecast page.
More about Philogen SpA
Philogen is an Italian-Swiss biotechnology company focused on the research and development of pharmaceutical products, particularly targeted anti-cancer drugs. Utilizing technologies like Antibody Phage Display Libraries and DNA-Encoded Chemical Libraries, Philogen develops ligands that deliver therapeutic agents specifically to tumor masses, minimizing damage to healthy tissues. The company aims to create innovative treatments for diseases lacking effective therapies, primarily in oncology but also potentially in chronic inflammatory diseases.
YTD Price Performance: 14.87%
Average Trading Volume: 9,439
Technical Sentiment Signal: Buy
Current Market Cap: €655M
For detailed information about PHIL stock, go to TipRanks’ Stock Analysis page.